Condition: Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma · Sponsor: Ning Jiang, M.D./Ph.D.
This study aims to compare the efficacy and safety of short-course definitive concurrent chemoradiotherapy plus immunotherapy followed by immunotherapy maintenance versus short-course definitive chemoradiotherapy plus immunotherapy maintenance in the treatment of locally advanced unresectable esophageal squamous cell carcinoma, and to exploratorily identify molecular biomarkers associated with treatment efficacy and toxicity.
This description comes directly from the study's public registry record.
Xiangzhi Zhu · +86 25 83283535 · 13182948068@163.com
Ning Jiang · +86 25 83283535 · njiang117@njmu.edu.cn
Always discuss trial participation with your own doctor first.
| Jiangsu Cancer Hospital /Jiangsu Institute of Cancer Research | Nanjing, Jiangsu, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07530094